Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women

Stefania Lamon-Fava, Margaret R. Diffenderfer, P. Hugh R. Barrett, Wing Yee Wan, Borbala Postfai, Chorthip Nartsupha, Gregory G. Dolnikowski, Ernst J. Schaefer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The distinct effects of the estrogen and progestin components of hormonal therapy on the metabolism of apolipoprotein (apo) B-containing lipoproteins have not been studied. We enrolled eight healthy postmenopausal women in a placebo-controlled, randomized, double-blind crossover study. Each subject received placebo, conjugated equine estrogen (CEE, 0.625 mg/day) and CEE plus medroxyprogesterone acetate (MPA, 2.5 mg/day) for 8 weeks in a randomized order, with a 4-week washout between phases. Main outcomes were the fractional catabolic rate (FCR) and production rate (PR) of apo B100 in triglyceride-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low -density lipoprotein (LDL) and of apo B48 in TRL. Compared to placebo, CEE increased TRL apo B100 PR (p = 0.04). CEE also increased LDL apo B100 FCR (p = 0.02), but this effect was offset by a significant increase in LDL apo B100 PR (p = 0.04). Adding MPA to CEE negated the CEE effects resulting in no significant changes in TRL apo B100 PR and LDL apo B100 FCR and PR relative to placebo. Relative to placebo, during CEE there was a trend toward a reduction in plasma apo B48 concentrations and PR (p = 0.07 and p = 0.12, respectively). Compared with CEE, CEE + MPA significantly increased TRL apo B48 FCR (p = 0.02) as well as apo B48 PR (p = 0.01), resulting in no significant changes in apo B48 concentration. Estrogen and progestin have independent and opposing effects on the metabolism of the atherogenic apo B100- and apo B48-containing lipoproteins.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalLipids
Volume53
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Apolipoprotein B-48
Apolipoproteins
Progestins
Lipoproteins
Estrogens
Kinetics
Triglycerides
LDL Lipoproteins
Placebos
Metabolism
IDL Lipoproteins
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Apolipoproteins B
Double-Blind Method
Cross-Over Studies
Plasmas

Cite this

Lamon-Fava, S., Diffenderfer, M. R., Barrett, P. H. R., Wan, W. Y., Postfai, B., Nartsupha, C., ... Schaefer, E. J. (2018). Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. Lipids, 53(2), 167-175. https://doi.org/10.1002/lipd.12011
Lamon-Fava, Stefania ; Diffenderfer, Margaret R. ; Barrett, P. Hugh R. ; Wan, Wing Yee ; Postfai, Borbala ; Nartsupha, Chorthip ; Dolnikowski, Gregory G. ; Schaefer, Ernst J. / Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. In: Lipids. 2018 ; Vol. 53, No. 2. pp. 167-175.
@article{4aa9adb6167847e4b0ddce958ebd1751,
title = "Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women",
abstract = "The distinct effects of the estrogen and progestin components of hormonal therapy on the metabolism of apolipoprotein (apo) B-containing lipoproteins have not been studied. We enrolled eight healthy postmenopausal women in a placebo-controlled, randomized, double-blind crossover study. Each subject received placebo, conjugated equine estrogen (CEE, 0.625 mg/day) and CEE plus medroxyprogesterone acetate (MPA, 2.5 mg/day) for 8 weeks in a randomized order, with a 4-week washout between phases. Main outcomes were the fractional catabolic rate (FCR) and production rate (PR) of apo B100 in triglyceride-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low -density lipoprotein (LDL) and of apo B48 in TRL. Compared to placebo, CEE increased TRL apo B100 PR (p = 0.04). CEE also increased LDL apo B100 FCR (p = 0.02), but this effect was offset by a significant increase in LDL apo B100 PR (p = 0.04). Adding MPA to CEE negated the CEE effects resulting in no significant changes in TRL apo B100 PR and LDL apo B100 FCR and PR relative to placebo. Relative to placebo, during CEE there was a trend toward a reduction in plasma apo B48 concentrations and PR (p = 0.07 and p = 0.12, respectively). Compared with CEE, CEE + MPA significantly increased TRL apo B48 FCR (p = 0.02) as well as apo B48 PR (p = 0.01), resulting in no significant changes in apo B48 concentration. Estrogen and progestin have independent and opposing effects on the metabolism of the atherogenic apo B100- and apo B48-containing lipoproteins.",
keywords = "Apolipoprotein B100, Apolipoprotein B48, Hormone therapy, Lipoprotein metabolism",
author = "Stefania Lamon-Fava and Diffenderfer, {Margaret R.} and Barrett, {P. Hugh R.} and Wan, {Wing Yee} and Borbala Postfai and Chorthip Nartsupha and Dolnikowski, {Gregory G.} and Schaefer, {Ernst J.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/lipd.12011",
language = "English",
volume = "53",
pages = "167--175",
journal = "Lipids",
issn = "0024-4201",
publisher = "Springer-Verlag London Ltd.",
number = "2",

}

Lamon-Fava, S, Diffenderfer, MR, Barrett, PHR, Wan, WY, Postfai, B, Nartsupha, C, Dolnikowski, GG & Schaefer, EJ 2018, 'Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women' Lipids, vol. 53, no. 2, pp. 167-175. https://doi.org/10.1002/lipd.12011

Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. / Lamon-Fava, Stefania; Diffenderfer, Margaret R.; Barrett, P. Hugh R.; Wan, Wing Yee; Postfai, Borbala; Nartsupha, Chorthip; Dolnikowski, Gregory G.; Schaefer, Ernst J.

In: Lipids, Vol. 53, No. 2, 01.02.2018, p. 167-175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women

AU - Lamon-Fava, Stefania

AU - Diffenderfer, Margaret R.

AU - Barrett, P. Hugh R.

AU - Wan, Wing Yee

AU - Postfai, Borbala

AU - Nartsupha, Chorthip

AU - Dolnikowski, Gregory G.

AU - Schaefer, Ernst J.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The distinct effects of the estrogen and progestin components of hormonal therapy on the metabolism of apolipoprotein (apo) B-containing lipoproteins have not been studied. We enrolled eight healthy postmenopausal women in a placebo-controlled, randomized, double-blind crossover study. Each subject received placebo, conjugated equine estrogen (CEE, 0.625 mg/day) and CEE plus medroxyprogesterone acetate (MPA, 2.5 mg/day) for 8 weeks in a randomized order, with a 4-week washout between phases. Main outcomes were the fractional catabolic rate (FCR) and production rate (PR) of apo B100 in triglyceride-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low -density lipoprotein (LDL) and of apo B48 in TRL. Compared to placebo, CEE increased TRL apo B100 PR (p = 0.04). CEE also increased LDL apo B100 FCR (p = 0.02), but this effect was offset by a significant increase in LDL apo B100 PR (p = 0.04). Adding MPA to CEE negated the CEE effects resulting in no significant changes in TRL apo B100 PR and LDL apo B100 FCR and PR relative to placebo. Relative to placebo, during CEE there was a trend toward a reduction in plasma apo B48 concentrations and PR (p = 0.07 and p = 0.12, respectively). Compared with CEE, CEE + MPA significantly increased TRL apo B48 FCR (p = 0.02) as well as apo B48 PR (p = 0.01), resulting in no significant changes in apo B48 concentration. Estrogen and progestin have independent and opposing effects on the metabolism of the atherogenic apo B100- and apo B48-containing lipoproteins.

AB - The distinct effects of the estrogen and progestin components of hormonal therapy on the metabolism of apolipoprotein (apo) B-containing lipoproteins have not been studied. We enrolled eight healthy postmenopausal women in a placebo-controlled, randomized, double-blind crossover study. Each subject received placebo, conjugated equine estrogen (CEE, 0.625 mg/day) and CEE plus medroxyprogesterone acetate (MPA, 2.5 mg/day) for 8 weeks in a randomized order, with a 4-week washout between phases. Main outcomes were the fractional catabolic rate (FCR) and production rate (PR) of apo B100 in triglyceride-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low -density lipoprotein (LDL) and of apo B48 in TRL. Compared to placebo, CEE increased TRL apo B100 PR (p = 0.04). CEE also increased LDL apo B100 FCR (p = 0.02), but this effect was offset by a significant increase in LDL apo B100 PR (p = 0.04). Adding MPA to CEE negated the CEE effects resulting in no significant changes in TRL apo B100 PR and LDL apo B100 FCR and PR relative to placebo. Relative to placebo, during CEE there was a trend toward a reduction in plasma apo B48 concentrations and PR (p = 0.07 and p = 0.12, respectively). Compared with CEE, CEE + MPA significantly increased TRL apo B48 FCR (p = 0.02) as well as apo B48 PR (p = 0.01), resulting in no significant changes in apo B48 concentration. Estrogen and progestin have independent and opposing effects on the metabolism of the atherogenic apo B100- and apo B48-containing lipoproteins.

KW - Apolipoprotein B100

KW - Apolipoprotein B48

KW - Hormone therapy

KW - Lipoprotein metabolism

UR - http://www.scopus.com/inward/record.url?scp=85043721417&partnerID=8YFLogxK

U2 - 10.1002/lipd.12011

DO - 10.1002/lipd.12011

M3 - Article

VL - 53

SP - 167

EP - 175

JO - Lipids

JF - Lipids

SN - 0024-4201

IS - 2

ER -